Tissue distribution of renadirsen sodium, a dystrophin exon-skipping antisense oligonucleotide, in heart and diaphragm after subcutaneous administration to cynomolgus monkeys

References

• Moat, S. J.; Bradley, D. M.; Salmon, R.; Clarke, A.; Hartley, L. Newborn Bloodspot Screening for Duchenne Muscular Dystrophy: 21 Years Experience in Wales (UK). Eur J. Hum Genet 2013, 21, 1049–1053. DOI: 10.1038/ejhg.2012.301.
   PubMed Web of Science ®Google Scholar
• Nowak, K. J.; Davies, K. E. Duchenne Muscular Dystrophy and Dystrophin: Pathogenesis and Opportunities for Treatment: Third in Molecular Medicine Review Series. EMBO Rep. 2004, 5, 872–876. DOI: 10.1038/sj.embor.7400221.
   PubMed Web of Science ®Google Scholar
• Ahn, A. H.; Kunkel, L. M. The Structural and Functional Diversity of Dystrophin. Nat. Genet. 1993, 3, 283–291. DOI: 10.1038/ng0493-283.
   PubMed Web of Science ®Google Scholar
• White, S.; Kalf, M.; Liu, Q.; Villerius, M.; Engelsma, D.; Kriek, M.; Vollebregt, E.; Bakker, B.; Van Ommen, G. J. B.; Breuning, M. H.; et al. Comprehensive Detection of Genomic Duplications and Deletions in The DMD Gene, by Use of Multiplex Amplifiable Probe Hybridization. Am. J. Hum. Genet. 2002, 71, 365–374. DOI: 10.1086/341942.
   PubMed Web of Science ®Google Scholar
• Melacini, P.; Vianello, A.; Villanova, C.; Fanin, M.; Miorin, M.; Angelini, C.; Dalla Volta, S. Cardiac and Respiratory Involvement in Advanced Stage Duchenne Muscular Dystrophy. Neuromuscul. Disord. 1996, 6, 367–376. DOI: 10.1016/0960-8966(96)00357-4.
   PubMed Web of Science ®Google Scholar
• Matsuo, M. Antisense Oligonucleotide-Mediated Exon-Skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy. JMA J. 2021, 4, 232–240. DOI: 10.31662/jmaj.2021-0019.
   PubMedGoogle Scholar
• Patterson, G.; Conner, H.; Groneman, M.; Blavo, C.; Parmar, M. S. Duchenne Muscular Dystrophy: Current Treatment and Emerging Exon Skipping and Gene Therapy Approach. Eur. J. Pharmacol. 2023, 947, 175675. DOI: 10.1016/j.ejphar.2023.175675.
   PubMed Web of Science ®Google Scholar
• Filonova, G.; Aartsma-Rus, A. Next Steps for the Optimization of Exon Therapy for Duchenne Muscular Dystrophy. Expert Opin. Biol. Ther. 2023, 23, 133–143. DOI: 10.1080/14712598.2023.2169070.
   PubMed Web of Science ®Google Scholar
• Roberts, T. C.; Wood, M. J. A.; Davies, K. E. Therapeutic Approaches for Duchenne Muscular Dystrophy. Nat. Rev. Drug Discov. 2023, 22, 917–934. DOI: 10.1038/s41573-023-00775-6.
   PubMed Web of Science ®Google Scholar
• Qi, L. L.; Rabinowitz, A.; Yun, C. C.; Yokota, T.; Yin, H. F.; Alter, J.; Jadoon, A.; Bou-Gharios, G.; Partridge, T. Systemic Delivery of Antisense Oligoribonucleotide Restorers Dystrophin Expression in Body-Wide Skeletal Muscles. Proc. Natl. Acad. Sci. USA 2005, 102, 198–203. DOI: 10.1073/pnas.0406700102.
   PubMed Web of Science ®Google Scholar
• Goyenvalle, A.; Griffith, G.; Babbs, A.; El Andaloussi, S.; Ezzat, K.; Avril, A.; Dugovic, B.; Chaussenot, R.; Ferry, A.; Voit, T.; et al. Functional Correction in Mouse Models of Muscular Dystrophy Using Exon-Skipping Tricyclo-DNA Oligomers. Nat. Med. 2015, 21, 270–275. DOI: 10.1038/nm.3765.
   PubMed Web of Science ®Google Scholar
• Townsend, D. W.; Yasuda, S.; Li, S.; Chamberlain, J. S.; Metzger, J. M. Emergent Dilated Cardiomyopathy Caused by Targeted Repair of Dystrophic Skeletal Muscle. Mol. Ther. 2008, 16, 832–835. DOI: 10.1038/mt.2008.52.
   PubMed Web of Science ®Google Scholar
• Wu, B.; Xiao, B.; Cloer, C.; Shaban, M.; Sali, A.; Lu, P.; Li, J.; Nagaraju, K.; Xiao, X.; Lu, Q. L. One-Year Treatment of Morpholino Antisense Oligomer Improves Skeletal and Cardiac Muscle Functions in Dystrophic Mdx Mice. Mol. Ther. 2011, 19, 576–583. DOI: 10.1038/mt.2010.288.
   PubMed Web of Science ®Google Scholar
• Study of DS-5141b in Patients with Duchenne Muscular Dystrophy. ClinicalTrials.gov ID NCT02667483. https://classic.clinicaltrials.gov/ct2/show/NCT02667483.
   Google Scholar
• Koizumi, M. 2′-O,4′-C-Ethylene-Bridged Nucleic Acids (ENATM) as Next-Generation Antisense and Antigene Agents. Biol. Pharm. Bull. 2004, 27, 453–456. DOI: 10.1248/bpb.27.453.
   PubMed Web of Science ®Google Scholar
• Koizumi, M. ENA® Oligonucleotides as Therapeutics. Curr. Opin. Mol. Ther. 2006, 8, 144–149.
   PubMed Web of Science ®Google Scholar
• Ito, K.; Takakusa, H.; Kakuta, M.; Kanda, A.; Takagi, N.; Nagase, H.; Watanabe, N.; Asano, D.; Goda, R.; Masuda, T.; et al. Renadirsen, a Novel 2’OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo. Curr. Issues Mol. Biol. 2021, 43, 1267–1281. DOI: 10.3390/cimb43030090.
   PubMed Web of Science ®Google Scholar
• Yu, R. Z.; Grundy, J. S.; Henry, S. P.; Kim, T. W.; Norris, D. A.; Burkey, J.; Wang, Y.; Vick, A.; Geary, R. S. Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides with 2’-O-(2-Methoxyethyl) Modifications. Mol. Ther. Nucleic Acids 2015, 4, e218. DOI: 10.1038/mtna.2014.69.
   PubMedGoogle Scholar
• Imai, S.; Suda, Y.; Mori, J.; Sasaki, Y.; Yamada, T.; Kusano, K. Prediction of Human Pharmacokinetics of Phosphorodiamidate Morpholino Oligonucleotides in Duchenne Muscular Dystrophy Patients Using Viltolarsen. Drug Metab. Dispos. 2023, 51, 1428–1435. DOI: 10.1124/dmd.123.001425.
   PubMed Web of Science ®Google Scholar
• Takakusa, H.; Iwazaki, N.; Nishikawa, M.; Yoshida, T.; Obika, S.; Inoue, T. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs. Nucleic Acid Ther. 2023, 33, 83–94. DOI: 10.1089/nat.2022.0054.
   PubMed Web of Science ®Google Scholar
• Geary, R. S.; Norris, D.; Yu, R.; Bennett, C. F. Pharmacokinetics, Biodistribution and Cell Uptake of Antisense Oligonucleotides. Adv. Drug Deliv. Rev. 2015, 87, 46–51. DOI: 10.1016/j.addr.2015.01.008.
   PubMed Web of Science ®Google Scholar
• Bosgra, S.; Sipkens, J.; de Kimpe, S.; den Besten, C.; Datson, N.; van Deutekom, J. The Pharmacokinetics of 2’-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 2019, 29, 305–322. DOI: 10.1089/nat.2019.0805.
   PubMed Web of Science ®Google Scholar
• Malecova, B.; Burke, R. S.; Cochran, M.; Hood, M. D.; Johns, R.; Kovach, P. R.; Doppalapudi, V. R.; Erdogan, G.; Arias, J. D.; Darimont, B.; et al. Targeted Tissue Delivery of RNA Therapeutics Using Antibody–Oligonucleotide Conjugates (AOCs). Nucleic Acids Res. 2023, 51, 5901–5910. DOI: 10.1093/nar/gkad415.
   PubMed Web of Science ®Google Scholar
• Desjardins, C. A.; Yao, M.; Hall, J.; O’Donnell, E.; Venkatesan, R.; Spring, S.; Wen, A.; Hsia, N.; Shen, P.; Russo, R.; et al. Enhanced Exon Skipping and Prolonged Dystrophin Restoration Achieved by TfR1-Targeted Delivery of Antisense Oligonucleotide Using FORCE Conjugation in Mdx Mice. Nucleic Acids Res. 2022, 50, 11401–11414. DOI: 10.1093/nar/gkac641.
   PubMed Web of Science ®Google Scholar
• Prakash, T. P.; Mullick, A. E.; Lee, R. G.; Yu, J.; Yeh, S. T.; Low, A.; Chappell, A. E.; Østergaard, M. E.; Murray, S.; Gaus, H. J.; et al. Fatty Acid Conjugation Enhances Potency of Antisense Oligonucleotides in Muscle. Nucleic Acids Res. 2019, 47, 6029–6044. DOI: 10.1093/nar/gkz354.
   PubMed Web of Science ®Google Scholar